摘要
近年来虽然艾滋病防治取得了巨大进展,HIV疫苗依然是人类彻底战胜艾滋病的重要"武器"。HIV疫苗的研发历程坎坷,多种技术路线的疫苗进入临床试验阶段,但尚未获得成功。本文通过查阅US Clinical Trials数据库(clinicaltrials.gov)和中国药物临床试验登记与信息公示平台数据库,根据疫苗的技术路线,包括传统疫苗、重组亚单位蛋白疫苗、重组病毒载体类疫苗、核酸疫苗,总结了近十年进入临床试验阶段的HIV疫苗,重点阐述了进入临床Ⅲ期的疫苗和最有潜力的疫苗。
In recent years, although great progress has been made in the prevention and treatment of AIDS, the HIV vaccine is still an important "weapon" for mankind to completely defeat AIDS. However, the development of the HIV vaccine is bumpy, and several HIV vaccines with multiple technical routes have entered the stage of human clinical trials,but have not yet been successful. This article summarizes the HIV vaccines that have entered human clinical trials in the past ten years by searching the US Clinical Trials database(ClinicalTrials. gov) and the Platform for drug clinical trial registration and information publicity in China, including traditional vaccines, recombinant subunit protein vaccines,recombinant viral vector vaccines, nucleic acid vaccines, focusing on the most promising HIV vaccines and vaccines in the phase Ⅲ stage.
作者
聂玲玲
黄维金
NIE Lingling;HUANG Weijin(National Institutes for Food and Drug Control,Key Laboratory of National Health Commission of the People's Republic of China for Research on Quality and Standardization of Biotech Products,Key Laboratory of Biological Product Quality Research and Evaluation of State Drug Administration,Beijing 102629,China)
出处
《中国艾滋病性病》
CAS
CSCD
北大核心
2022年第2期220-227,共8页
Chinese Journal of Aids & STD
基金
国家“十三五”重大专项课题资助项目(2018ZX10731101-002-006)。
作者简介
第一作者:聂玲玲(1985-),女,河北省保定市人,高级工程师,从事疫苗检定方法研究。Email:nielingling@nifdc.org.cn;通信作者:黄维金,Email:huangweijin@nifdc.org.cn。
